Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Globus Medical Inc (GMED): This Medical Device Maker Looks Like a Good Pick

Page 1 of 2

Globus Medical Inc (NYSE:GMED)Globus Medical Inc (NYSE:GMED) has been attracting investment from many famous investors including Steven Cohen, Joel Greenblatt, and Chuck Royce. Since the beginning of the year, it has experienced a sweet rise of nearly 46% from around $11 per share to more than $15 per share. Is the run up now over for this stock? Or would it continue to march higher? Let’s take a closer look.

Consistent growth in top and bottom lines

Globus Medical Inc (NYSE:GMED) is the developer of more than 110 products for the treatment of patients with spine disorders, with two main product categories: Innovative Fusion products and Disruptive Technology products. Most of its revenue, $238.7 million, or 61.8% of the total 2012 revenue, was generated from the the Innovative Fusion product category, while the Disruptive Technology product category contributed nearly $147.3 million in sales in 2012. The majority of its sales, $355.6 million, were derived in the U.S.

In the past three years, Globus Medical Inc (NYSE:GMED) has experienced consistent growth in both top and bottom lines. Revenue has increased from $288 million in 2010 to $386 million in 2012 while net income has risen from $54 million to $74 million during the same period. In 2012, the company generated $77 million in operating cash flow and $52 million in free cash flow. What I like about the company is its strong, debt-free balance sheet. As of March 2013, it had $408 million in equity, $162 million in cash, and no debt.

The cheapest valued company among its peers

At $15.30 per share, Globus Medical Inc (NYSE:GMED) is worth nearly $1.4 billion. The market values the company at 9.6 times EV/EBITDA. Compared to its peers NuVasive, Inc. (NASDAQ:NUVA) and Stryker Corporation (NYSE:SYK), it is the cheapest valued among the three.

NuVasive, Inc. (NASDAQ:NUVA) is trading at around $22.20 per share with a total market cap of $982 million. It has a much higher EV multiple of 11.65. NuVasive, Inc. (NASDAQ:NUVA) has kept expanding its footprint via acquisitions. In the beginning of May, it announced that it has acquired ANC, a spine implant maker in Dayton, Ohio. This acquisition could be considered a vertical acquisition, as ANC has been one of the company’s implant suppliers. The total purchase price is around $4.5 million.

This vertical integration is expected to bring significant synergy for NuVasive, driving the company’s long-term profitability. Alex Lukianov, the company’s Chairman and CEO said: “Bringing portions of our manufacturing in house is a key element of our ongoing commitment to improve operating profitability as we grow toward $1 billion in revenue and beyond. With Speed of Innovation as a fundamental cornerstone of our success, the acquisition will reduce the time from the concept of a new idea to ultimate market introduction, enabling development and manufacturing to work seamlessly in launching our innovative solutions.”

Page 1 of 2
Loading Comments...